Tobias Welponer

8PUBLICATIONS
20CO-AUTHORS
Major global burdens of diseaseSocial determinants of healthSocial epidemiologyCancer geneticsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 10, 2025
Core outcome domain sets for clinical trials in epidermolysis bullosa - a COSEB protocol to achieve consensus on "what" to measure.

Eva W H Korte, Peter C van den Akker, Dimitra Kiritsi

|Jul 28, 2024
Systematic review on antipruritic therapies for patients with Epidermolysis bullosa.

Tobias Welponer, Christian Puttinger, Eva W H Korte

|Jun 12, 2024
Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa.

Eva W H Korte, Anna M G Pasmooij, Maria C Bolling

|Oct 04, 2023
Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting.

Eva W H Korte, Phyllis I Spuls, Peter C van den Akker

|Sep 05, 2023
Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.

T Welponer, D D Weber, L Trattner

|May 21, 2023
Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies.

R Lang, T Welponer, E Richtig

Pageof 2

Frequent Collaborators

5 joint publications

Marieke C Bolling

5 joint publications

Eva W H Korte

4 joint publications

Verena Wally

4 joint publications

Peter C van den Akker